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ABSTRACT
A growing body of evidence suggests that cancer stem cells (CSC) have the 
unique biological properties necessary for tumor maintenance and spreading, and 
function as a reservoir for the relapse and metastatic evolution of the disease by 
virtue of their resistance to radio- and chemo-therapies. Thus, the efficacy of a 
therapeutic approach relies on its ability to effectively target and deplete CSC. In this 
study, we show that CSC-enriched tumorspheres from breast cancer cell lines display 
an increased L-Ferritin uptake capability compared to their monolayer counterparts 
as a consequence of the upregulation of the L-Ferritin receptor SCARA5. L-Ferritin 
internalization was exploited for the simultaneous delivery of Curcumin, a natural 
therapeutic molecule endowed with antineoplastic action, and the MRI contrast agent 
Gd-HPDO3A, both entrapped in the L-Ferritin cavity. This theranostic system was 
able to impair viability and self-renewal of tumorspheres in vitro and to induce the 
regression of established tumors in mice. In conclusion, here we show that Curcumin-
loaded L-Ferritin has a strong therapeutic potential due to the specific targeting of 
CSC and the improved Curcumin bioavailability, opening up the possibility of its use 
in a clinical setting.
INTRODUCTION
The occurrence of resistance to chemotherapeutic 
drugs, tumor recurrences and metastases formation show 
the difficulties in finding effective cancer treatments 
and raise the question whether current anti-cancer 
therapies target the right cancer cell population. There 
is a growing concern that the commonly used treatments 
might indeed miss a small population of tumor cells 
called “tumor-initiating cells” or “cancer stem cells” 
(CSC), composed of stem-like cells that play a critical 
role in cancer progression. Like normal stem cells, 
CSC have the capacity to self-renew and to give rise 
to a more differentiated progeny, and share common 
signalling pathways. According to the CSC theory, CSC 
can be: i) the source of all the tumor cells present in a 
malignant tumor and ii) responsible for tumor relapse 
and dissemination, being associated to the resistance to 
radiotherapy and to the conventional chemotherapeutic 
agents [1]. CSC have been identified in several human 
solid tumors and prospectively isolated through specific 
markers [2], although there is no general consensus on the 
best markers to identify these cells [3]. In human breast 
carcinoma, CSC have been identified for the first time by 
Al Hajj et al. [4] as a rare population of CD44+/CD24−/low 
cells. Furthermore, CSC have the ability to survive and 
proliferate in anchorage-independent conditions giving 
rise to non-adherent spheres called tumorspheres that 
can be selectively cultured and expanded. This property 
was first described for neuronal progenitors [5] and then 
extended to progenitor cells of the mammary gland [6], 
to breast cell lines [7-9], and to human and murine breast 
carcinomas [10]. Given the central role of CSC in tumor 
progression, spreading and relapse, the cure for cancer 
might rely on CSC eradication. On the light of this 
therapeutic implication, several CSC-targeted approaches 
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are being studied. These approaches range from indirect 
strategies, such as antiangiogenic therapies [1], to direct 
targeting, pursued through differentiation therapies, 
reversal of resistance mechanisms [1], and immunotherapy 
[11-13]. Another promising strategy consists in the 
identification of new and more specific biomarkers related 
to CSC status, which could serve as new targets, as we 
previously described [8, 9]. Moreover, these targets could 
be used for the development of new diagnostic tools able 
to provide an insight into the frequency of CSC within 
the tumor. Based on evidences obtained from both 
epidemiological and molecular studies, new insights are 
emerging linking the presence of excess iron and altered 
iron metabolism to cancer [14, 15]. Recently, Schonberg 
et al. [16] have demonstrated an enhanced iron scavenging 
ability in CSC of glioblastoma multiforme, due to a 
significant overexpression of the transferrin receptor 
(TfR) and a consequent increase in transferrin uptake, 
which is indicative of increased tumorigenicity. Therefore, 
targeting iron regulation within tumor-specific pathways 
could represent a potential approach for the development 
of new effective anti-cancer treatments.
In this study, we exploited the sphere-forming 
ability of CSC to selectively enrich the stem-like cell 
population present in a human (MDA-MB-231) and 
murine (TUBO) breast cancer cell lines, as described in 
[8], and for the first time we demonstrated that the uptake 
of L-Ferritin increased in CSC-enriched tumorspheres 
generated from both cell lines compared to their 
more differentiated counterparts. We surmise that this 
behaviour may be associated to their enhanced expression 
of the L-Ferritin receptor Scavenger Receptor Class A 
member 5 (SCARA5) that mediates Ferritin endocytosis 
[17]. Ferritin is the main iron storage protein and is 
composed of 24 subunits of heavy (H)- or light (L)-chain 
polypeptides that are present at different ratios in various 
organs to form a cage architecture of 12 nm in external 
diameter, with an inner cavity of 8 nm [18]. Once deprived 
of iron, this cavity can be used for the selective delivery of 
imaging and therapeutic agents to cells expressing Ferritin 
receptors [19]. The use of these nanotheranostic agents 
permits the non-invasive analysis of the pharmacokinetics 
and biodistribution of the nanomedicine formulation. 
Consequently, it is possible to monitor the efficacy of the 
therapy in real time and thereby to adapt the treatment 
regimens [20-22]. Several papers have explored the use 
of H-Ferritin to deliver selectively doxorubicin to cancer 
cells [23, 24]. In this contest, we have previously reported 
that the selective uptake of native horse spleen Ferritin 
and Apoferritin (composed by 85% and 15% L and H 
chains, respectively) loaded with MRI contrast agents 
and the anticancer drug Curcumin in the human breast 
cancer cell line MCF7 causes a significant reduction in 
cell proliferation in vitro [25]. Curcumin has been selected 
as therapeutic agent since it has been reported to exhibit 
anticancer activity in vitro and to be highly tolerated 
when administered to patients [26]. However, its poor 
water solubility and low bioavailability hampers its use 
as anti-cancer drug [27]. Therefore, loading Curcumin 
into Apoferritin can represent a solution for its delivery 
to cancer cells in vivo. Herein, we show that Apoferritin 
can be exploited for the simultaneous delivery of Gd-
based MRI contrast agents and Curcumin for breast 
CSC targeting. Moreover, we show that administration 
of Curcumin-loaded Apoferritin leads to the regression 
of breast tumors in vivo. This approach could potentially 
enhance the responsiveness to current anticancer treatment 
regimens and might reduce the risk of relapse and 
dissemination of the disease.
RESULTS AND DISCUSSION
SCARA5 is upregulated in breast CSC
A transcriptional analysis comparing the 
transcription profile of Her2+ murine TUBO cells cultured 
as monolayer with those of the first three in vitro passages 
of their derived CSC-enriched tumorspheres using 
MouseWG-6 v2.0 Illumina beadchips (GSE21451) [28] 
proved that SCARA5 is upregulated in tumorspheres 
(Figure 1A). SCARA5 protein expression increased from 
TUBO to tumorsphere-derived cells, as demonstrated 
by the representative images (panel B, C) and by the 
quantification of fluorescence intensity (panel D) reported 
in Figure 1. This enhanced expression is not restricted 
to TUBO-derived CSC, as it was also observed in 
tumorspheres derived from human triple negative breast 
cancer (TNBC) cell line MDA-MB-231 (Figure 1E-1G), 
further suggesting that SCARA5 may be a promising 
target of breast CSC.
Breast CSC internalize more Ferritin than 
differentiated cancer cells
Since SCARA5 mediates L-Ferritin uptake [29], the 
first step of this study was the evaluation of the ability of 
MDA-MB-231 and TUBO tumorspheres to take up Ferritin 
from the medium compared to their corresponding more 
differentiated cells. For this purpose, horse spleen Ferritin, 
composed mostly of L-Ferritin chains and containing ca. 
1000 iron atoms per protein, was used without any further 
modification. The experimental protocol consisted in 
the measurement of the amount of iron internalized by 
cells upon 24 hours of incubation in Ferritin-containing 
medium. The amount of internalized Ferritin was assessed 
by the ICP-MS determination of the intracellular iron 
content. The amount of internalized iron was significantly 
higher in tumorspheres than in differentiated cells, and 
increased with Ferritin concentration in both TUBO 
(Figure 2A) and MDA-MB-231 (Figure 2B) cell lines.
Ferritin contains a superparamagnetic ferrihydrite 
(5Fe
2
O
3
·9H
2
O) crystal that increases the transverse NMR 
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relaxation rate (R
2
) of solvent water protons, causing a 
negative contrast in the corresponding MR images [30]. 
In order to assess whether native Ferritin can be exploited 
as a natural MRI probe for CSC detection, T
2
-weighted 
MR images were acquired following Ferritin incubation 
on both MDA-MB-231 and TUBO cells and their derived 
tumorspheres. Figure 2C shows that tumorspheres 
incubated with Ferritin displayed a markedly lower signal 
intensity when compared to untreated tumorspheres, while 
only small changes in signal intensity (SI) were observed 
in differentiated cells incubated in the absence or in the 
presence of Ferritin, respectively (Supplementary Material, 
Supplementary Table S1). Since spheroid diameter range 
is between 80 and 120 μm, TUBO-derived tumorspheres 
incubated 24 hours with 0.52 μM Ferritin were detectable 
as isolated spots after their dispersion in agar (Figure 2D). 
Altogether, these data show that Ferritin-based contrast 
agents may be exploited for the MRI detection of CSC. 
The specificity of the uptake was assessed by carrying out 
a competition study by incubating cells for 24 hours in 
the presence of an excess of native Apoferritin. In both 
MDA-MB-231- and TUBO-derived tumorspheres, the 
iron uptake measured by ICP-MS decreased of about 60% 
and 66%, respectively, confirming that iron uptake was 
mediated by Ferritin specific receptors. To ensure that 
the uptake of Ferritin by CSC is specifically mediated by 
SCARA5, we assessed the effect of SCARA5 silencing on 
the ability of cells to internalize Ferritin. TUBO-derived 
Figure 1: SCARA5 expression is upregulated in tumorspheres. A. Relative transcript expression level of SCARA5 in TUBO 
cells and in three different tumorsphere passages. B, E. Representative images of TUBO and MDA-MB-231 cells or of C, F. their derived 
tumorspheres stained with an anti-SCARA5 mAb (red). Nuclei were counterstained with DAPI (blue). Scale bar, 20 μM. D, G. Graphs 
represent the mean ± SEM of the corrected total cell fluorescence (CTCF), calculated on at least 100 cells per sample as a quantification of 
SCARA5 expression in TUBO and MDA-MB-231 cells or in their derived tumorspheres.
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Figure 2: CSC display a higher Ferritin uptake than differentiated cells. A, B. ICP-MS determination of the intracellular 
iron content of TUBO (A) and MDA-MB-231 (B) cells and their derived tumorspheres cultured for 24 hours with or without Ferritin 0.17 
and 0.52 μM. Graphs show the mean ± SEM of internalized iron moles every mg of cell proteins from 3 independent experiments. C. A 
representative T
2
-weighted RARE MR image of an agar phantom containing TUBO and MDA-MB-231 cells (both differentiated and 
tumorspheres) incubated or not for 24 hours with L-Ferritin 0.52 μM. D. MRI of TUBO tumorspheres dispersed in agar. Each hypo-intense 
spot corresponds to the signal arising from one tumorsphere. E, F. TUBO derived tumorspheres were transfected with a siRNA to SCARA5 
or a scrambled siRNA, and 48 hours after incubated with L-Ferritin for additional 24 hours. (E) Representative immunoblot of SCARA5 
expression 48 hours after cell transfection. Vinculin expression was used as internal control. (F) Graph showing mean ± SEM of iron moles 
every mg of cell proteins, evaluated by ICP-MS, from 3 independent experiments. *p<0.05, Student’s t test.
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tumorspheres were incubated with a siRNA specific to 
SCARA5 or with a negative control scrambled siRNA, 
and the levels of SCARA5 protein were analyzed 24, 
48 and 72 hours after transfection. SCARA5 transcript 
silencing (Supplementary Material, Supplementary Figure 
S1), led to a threefold decrease in SCARA5 protein level 
48 hours after transfection, and this was maintained for 
the subsequent 24 hours (Figure 2E, Supplementary 
Figure S1). Hence, 48 hours after transfection, cells were 
incubated with 0.52 μM Ferritin for 24 hours. As shown 
in Figure 2F, the amount of iron internalized by cells 
treated with siRNA to SCARA5 was significantly lower 
than that internalized by control cells, thus confirming that 
SCARA5 mediates Ferritin uptake in breast CSC.
In order to further confirm that breast tumorspheres 
take up more Ferritin than their differentiated counterpart, 
Apoferritin was labelled with FITC on its external surface 
(hereafter referred to as APO-FITC), and TUBO cells and 
their derived tumorspheres were incubated for 24 hours 
in the presence of APO-FITC. Flow cytometric analysis 
revealed that APO-FITC was internalized by both TUBO 
and tumorspheres, but its intake in tumorspheres was 
significantly higher, as demonstrated by their enhanced 
mean fluorescence intensity (MFI, Figure 3A) when 
compared to TUBO cells. Of note, all cells expressing the 
stem cell marker Sca-1 [8], only present in tumorspheres, 
displayed a higher APO-FITC uptake than the remaining 
cells (Figure 3B, Sca1+ APO-FITChigh cells in the red 
boxes), suggesting that Ferritin uptake is higher in CSC 
than in more differentiated cells. Similarly, a small 
amount of APO-FITC was internalized in MDA-MB-231 
differentiated cells, while its internalization in their 
derived tumorspheres was significantly higher (Figure 
3C).
Uptake and intracellular distribution of 
rhodamine isothiocyanate labelled apoferritin 
(Apo-Rhod)
In order to perform a dose-response study using low 
Apoferritin concentrations, thus evaluating its affinity to 
SCARA5 receptors, Apoferritin was conjugated on its 
external surface with Rhodamine isothiocyanate (hereafter 
referred to as APO-Rhod), and incubated 24 hours with 
TUBO, MDA-MB-231 and their derived tumorspheres. 
Figure 4A shows the amount of APO-Rhod taken up by 
cells, determined using a calibration curve performed with 
a Rhodamine standard solution. These results confirm that 
the amount of internalized APO-Rhod was significantly 
higher in tumorspheres than in differentiated cells even at 
nanomolar concentrations, which is an indication of the 
high affinity of Apoferritin for SCARA5 receptor.
In order to assess whether the presence of 15% of 
H-chains in the horse spleen Ferritin used in this study 
can mediate its uptake through H-Ferritin receptors, a 
further competition study was carried out by incubating 
both MDA-MB-231 and TUBO tumorspheres for 24 hours 
with APO-Rhod in the presence of a 10-fold excess of 
recombinant H-Ferritin [31, 32]. The H-Ferritin excess did 
not affect the amount of APO-Rhod internalized in both 
MDA-MB-231 and TUBO tumorspheres (Figure 4B) thus 
excluding the involvement of H-Ferritin receptors in the 
internalization of Horse spleen Apoferritin.
To explore the underlying internalization 
mechanism, APO-Rhod was incubated with TUBO-
derived tumorspheres for fluorescence microscopy 
observation (Figure 4). Cells were then stained either for 
the early endosomal marker EEA-1 (panels C-F) or for 
the lysosomal marker LAMP-1 (panels G-L) to observe 
the process of APO-Rhod cellular trafficking. Two hours 
after incubation, APO-Rhod was located in the cytoplasm 
of most cells where it colocalized with early endosomes, 
as shown in panel F. LAMP-1 was distributed throughout 
the cytoplasm and the codistribution of APO-Rhod with 
LAMP-1 signal was circumscribed to the granular regions 
in the cytoplasm of some cells (Figure 4, panel L). These 
observations indicate that APO-Rhod was delivered to 
early endosomes after internalization. In the canonical 
receptor-mediated endocytosis pathway, early endosomes 
gradually mature to became late endosomes that then 
converge in lysosomes [33]. Most probably, APO-Rhod 
partly follows this path after internalization, since it 
colocalizes with the lysosomal marker LAMP-1.
Uptake of apoferritin loaded with Gd-HPDO3A 
MRI contrast agent and Curcumin (Gd-APO-
curcumin)
Despite its structural stability under physiological 
conditions, Ferritin displays a pH-dependent de-assembly, 
which can be exploited to load it with both therapeutic 
agents and imaging probes. Indeed, there are many 
examples where Ferritin nanoarchitecture was broken 
down in acidic environment and restored by retuning the 
pH to 7.4, after the entrapment of the desired solutes in 
its inner cavity [22, 34]. Using this procedure, Curcumin 
and the commercially available MRI contrast agent Gd-
HPDO3A, neutral and safe even at high concentrations 
[35], were entrapped in the Apoferritin cavity (Figure 5A). 
Curcumin was selected as therapeutic agent since it has 
been reported to exhibit anti-oxidant, anti-inflammatory, 
anti-microbial and anti-cancer activity in vitro and 
in animal models of several diseases, such as acute 
hepatitis, acute ileitis, neuroinflammation, ischaemia and 
cancer [36]. Its anti-cancer activity is operated through 
modulation or inhibition of multiple molecular pathways 
[37]. Furthermore, during the past few years, a number 
of studies have suggested that Curcumin may have direct 
or indirect influence on CSC self-renewal pathways, 
including Wnt/b-catenin, sonic hedgehog, and Notch 
[38-40]. Another important property is that, unlike other 
known chemotherapeutic compounds, Curcumin does not 
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cause any damage to normal cells [41]. Since SCARA5 
is also expressed in the liver, the observation that 
Curcumin had no effect on normal rat hepatocytes [41] 
is essential to promote its use as a valid chemopreventive 
and chemotherapeutic agent for CSC using Apoferritin 
as a delivery platform. Furthermore, loading Curcumin 
into its protein cavity improves Curcumin bioavailability 
and stability under physiological conditions, maintaining 
its peculiar pharmacological properties [22]. Curcumin-
loaded Apoferritin (APO-Curcumin) stability was assessed 
spectrophotometrically by measuring absorbance decrease 
at 430 nm. In the first 2 hours the absorbance showed a 
small decrease (15%), then it remained essentially constant 
during the entire experimental time (48 hours). Without 
Apoferritin, more than 90% of Curcumin decomposed 
rapidly (30 minutes) in buffer at neutral pH as already 
reported by Zebib et al. [42].
Using the protocol described above, the number of 
molecules that remained in Apoferritin inner cavity after 
the dissociation/reassociation procedure was 228 ± 48 and 
9.6 ± 2 for Curcumin and Gd-HPDO3A, respectively. Gd-
APO-Curcumin is stable for at least 48h as assessed by 
Figure 3: CSC display a higher APO-FITC uptake than differentiated cells. FACS analysis of TUBO and MDA-MB-231 
cells and their derived tumorspheres cultured with or without APO-FITC for 24 hours. A, C. Representative histograms of untreated (open 
histograms) or APO-FITC treated (gray histograms) TUBO (A) and MDA-MB-231 (C) cells and tumorspheres. Numbers show mean 
fluorescent intensity (MFI), the graphs show the mean ± SEM of APO-FITC MFI observed in cells and tumorspheres from 4 independent 
experiments. B. Representative dot plots of APO-FITC and Sca-1 expression in TUBO and tumorspheres. Numbers in quadrants show the 
percentage of APO-FITChigh Sca1+ cells (evidenced by the red boxes), the graph shows the mean ± SEM of the percentage of APO-FITChigh 
Sca-1+ cells in TUBO and tumorspheres from 4 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001; Student's t test.
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measuring absorbance at 430 nm [17]. The T1-weighted 
MRI image, recorded after 24 hours incubation in the 
presence of Gd-APO-Curcumin (2.7 μM), showed 
that the signal arising from labelled tumorspheres 
was clearly hyperintense compared to the untreated 
control tumorspheres for both cell lines (Figure 5B and 
Supplementary Materials, Supplementary Table S2). 
On the contrary, no significant signal enhancement was 
observed in Gd-APO-Curcumin-treated differentiated cells 
when compared to untreated cells. These observations 
were confirmed by the significantly higher amount of Gd 
taken-up by tumorspheres, measured by ICP-MS (Figure 
5C). On the basis of the ICP-MS Gd measurements, it was 
possible to calculate the intracellular Gd, and consequently 
Curcumin, concentrations. In fact, since the Curcumin/
Gd ratio in the Apoferritin preparation was 16, estimated 
intracellular Curcumin concentrations of 1400 and 460 
μg/g were obtained for MDA-MB-231 and TUBO derived 
tumorspheres, respectively.
APO-Curcumin induces cell death and reduces 
self-renewal of CSC
In order to seek whether APO-Curcumin is able 
to induce inhibitory effects on CSC survival and self-
renewal, TUBO cells and their derived tumorspheres 
where incubated in the presence or absence of APO-
Curcumin for different time intervals, and cell death was 
evaluated by citofluorimetric analysis with Annexin V and 
propidium iodide staining. As shown in Figure 6A, APO-
Curcumin did not induce cell death in TUBO cells, while 
progressively caused cell death in tumorspheres when 
compared to untreated cells. Of note, APO-Curcumin 
was more efficient than free Curcumin in inducing cell 
Figure 4: Uptake and intracellular distribution of Apo-Rhod. A. Dose-response curve obtained by incubating different 
concentrations of APO-Rhod 24 hours with TUBO (red dotted line), MDA-MB-231 (black dotted line) and their derived tumorspheres (red 
and black continuous lines respectively). B. Apo-Rhod concentrations were determined by measuring fluorescence (ex/em 555/575 nm) on 
cytosolic extracts and were normalized to the cell proteins. Fluorescence intensity (au) of cytosolic extracts of TUBO and MDA-MB-231 
derived tumorspheres, incubated in the absence (white bars) or in the presence of a 10 fold excess of H-Apoferritin. C-L. Representative 
images of TUBO derived tumorspheres incubated for 2 hours at 37°C with APO-Rhod (red, D and H) and stained with an anti-EEA1 
antibody (green, C) or an anti-LAMP-1 antibody (green, G). Nuclei were counterstained with DAPI (blue, E and I). The co-localization 
between APO-Rhod and EEA1 or LAMP-1 is shown in the merged images of panels F and L, respectively. Scale bar, 10 μM.
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death in tumorspheres (Figure 6B). This enhanced effect 
was not due to any toxicity of the protein itself, since 
treatment with Apoferritin did not induce cell death in 
either TUBO or tumorspheres (Figure 6B), but likely 
to the ability of APO-Curcumin to enhance Curcumin 
uptake by CSC. APO-Curcumin and Curcumin affected 
Figure 5: Gd-APO-Curcumin uptake is higher in CSC than in differentiated cells. A. Schematic representation of Gd-APO-
Curcumin preparation. B. A representative T1-weighted spin echo image of an agar phantom containing TUBO and MDA-MB-231 (both 
differentiated and tumorspheres) cells incubated or not for 24 hours with Gd-APO-Curcumin (2.7 μM in protein). C. Mean ± SEM of 
internalized Gd moles every mg of cell proteins from 3 independent experiments, measured by ICP-MS as in (B). *P < 0.05; Student's t test.
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not only tumorsphere viability, but also CSC self-renewal 
capacity as shown by a decreased ability of treated cells to 
re-generate tumorspheres, which on the contrary was not 
hindered by treatment with Apoferritin alone (Figure 6C). 
None of these compounds altered TUBO cell morphology 
(Figure 6D, upper panels), while tumorspheres cultured in 
presence of Curcumin and APO-Curcumin were smaller 
than those cultured in medium alone or with Apoferritin 
Figure 6: APO-Curcumin induces cell death and reduces self-renewal in tumorspheres. TUBO A-D. and MDA-MB-231 E-
H. cells were cultured as monolayer or tumorpsheres in presence of Apoferritin, APO-Curcumin or Curcumin. (A, E) After 24, 48, 72 or 96 
hours, cells were stained with Annexin-V and PI and analyzed by FACS. The graphs show means ± SEM of the ratio of dead cells between 
APO-Curcumin-treated and untreated cells, calculated as described in M&M. (B, F) Graphs showing means ± SEM of the ratio of the 
percentage of dead cells present in samples treated for 96 hours with Apoferritin, APO-Curcumin or Curcumin in comparison to untreated 
samples. (C, G) The graphs show means ± SEM of the number of spheres generated every 103 cells plated in the absence or presence of 
Apoferritin, APO-Curcumin or Curcumin. (D, H) Representative images of differentiated (upper panels) or tumorspheres (lower panels) 
cultured for 96 hours with the different treatments. Magnification 40X, scale bars 100 μm. All experiments were repeated at least 4 times. 
*P < 0.05; **P < 0.01; Student's t test.
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(Figure 6D, lower panels). The ability of APO-Curcumin 
to target CSC and decrease their survival and self-renewal 
is not restricted to the TUBO model, since similar results 
were obtained with MDA-MB-231 cells (Figure 6E-
6H). While the increased effect of APO-Curcumin on 
tumorspheres compared to differentiated cells can be 
explained by tumorspheres’ increased expression of 
SCARA5 receptor, the reason why even free Curcumin 
(50 μM) affects tumorspheres but not differentiated cells 
is more speculative. It has been shown by others [38, 43] 
that Curcumin acts primarily on undifferentiated stem 
and progenitor cells rather than on more differentiated 
cells from mammary tissue and breast cancer cell lines. 
This effect appears to be mediated, at least in part, by the 
inhibition of intracellular signalling pathways that are 
upregulated in CSC [38]. It is therefore highly likely that 
a similar mechanism of action occurs also in our model.
APO-Curcumin inhibits breast cancer growth 
in vivo
To explore the efficacy of APO-Curcumin on 
established tumors in vivo, we set up a model that 
consists in the subcutaneous (s.c.) implantation of TUBO-
derived tumorspheres into syngeneic BALB/c mice. 
After implantation, these cells maintain a prevalent CSC 
phenotype, as demonstrated by the presence of an higher 
level of both CD44+/CD24- and Aldefluor+ expressing 
cells when compared to tumors generated by TUBO cells 
(Supplementary Material, Supplementary Figure S2). 
When tumors reached 2 mm mean diameter, mice were 
treated with APO-Curcumin or Apoferritin (10 mg/Kg of 
Curcumin and 53 mg/Kg of protein) intravenously (i.v.) 
every 3 days, or left untreated (Figure 7). The extremely 
low Curcumin water solubility prevents its direct i.v. 
Figure 7: APO-Curcumin treatment delays CSC-induced tumor growth in vivo. A-C. BALB/c mice were challenged s.c. with 
TUBO-derived tumorspheres and left untreated (A, gray lines) or treated i.v. with Apoferritin (B, 53 mg/Kg; black lines) or APO-Curcumin 
(C, 10 mg/Kg of Curcumin and 53 mg/Kg of protein; red lines) every 3 days, starting when their tumor reached 2 mm mean diameter. 
Each line depicts the growth of a single tumor. D. Kaplan-Meier survival curves. APO-Curcumin vs Apoferritin treated mice: P=0.0189; 
Apoferritin treated mice vs Untreated mice: P = 0.5; APO-Curcumin treated mice vs Untreated mice: P= 0.0054, Log-rank (Mantel-Cox) 
Test. Data were cumulated from two independent and concordant experiments.
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administration without exploiting a nanoformulation/
emulsion, therefore it was not possible to insert a 
Curcumin-treated group. Whereas virtually all tumors 
grew progressively in untreated or Apoferritin-treated 
mice (Figure 7A, 7B and Table 1), they did not progress 
or eventually regressed in about 60% of APO-Curcumin 
treated mice (Figure 7C and Table 1).
Considering the animal survival, whereas all 
untreated mice died at the end of the experiment, about 
60% of APO-Curcumin treated mice were still alive, 
compared to only 10% in the Apoferritin treated group 
(Figure 7D; P=0.018, Chi square test), suggesting that 
Curcumin-loaded Apoferritin may represent a promising 
tool for breast cancer treatment.
In order to verify that APO-Curcumin is not toxic to 
the liver, being SCARA 5 also expressed on hepatocytes, 
histological assessment of liver damage was carried out 
at the end point of the treatment. Periportal hepatocytes 
from both Apoferritin and APO-Curcumin treated animals 
did not show any injury but only a moderate degree 
of vacuolar degeneration, which is compatible with 
lysosomal compartment enlargement due to the endocytic 
uptake of the nanodevice (Supplementary Material, 
Supplementary Figure S3).
In conclusion, in this work it was shown that 
both human and mice breast CSC display an increased 
L-Ferritin uptake capability compared to their more 
differentiated counterparts. This is mediated at least 
in part by the upregulation of the L-Ferritin receptor 
SCARA5. These results open new horizons in the design 
of targeting strategies for the eradication of CSC, which 
are usually highly resistant to conventional chemo- and 
radiotherapy. Indeed, the increased L-Ferritin uptake can 
be exploited for the delivery of Curcumin to CSC, as the 
loading of Curcumin into L-Apoferritin does not cause 
any reduction of its affinity for the SCARA5 receptor. Of 
note, loading Curcumin into Apoferritin not only enables 
specific targeting to SCARA5-expressing cells, and thus to 
breast CSC, but also improves Curcumin bioavailability, 
opening up the possibility of in vivo treatments. Our 
in vivo results highlight the therapeutic potential of 
APO-Curcumin. However, to improve the clinical 
translatability of this approach, further experiments are 
needed in order to explore the synergistic effect of APO-
Curcumin and classical chemotherapy. In this way, the 
elimination of CSC, exerted by APO-Curcumin, could 
be accompanied by the eradication of more differentiated 
tumor cells, leading to overcome tumor resistance and 
reduce recurrence. The relatively low sensitivity of MRI 
hampers the use of Gd-APO-Curcumin for the in vivo 
detection of CSC that represent a very low proportion of 
the tumor mass. However, this important objective might 
be achieved by developing more sensitive Apoferritin 
based PET or optical probes, which could provide new 
theranostic tools to improve breast patient stratification 
and monitoring of their response to therapy.
MATERIALS AND METHODS
Preparation of Gd-HPDO3A and Curcumin 
loaded Apoferritin (Gd-APO-Curcumin)
Gd-HPDO3A (ProHance) was kindly provided by 
Bracco Imaging S.p.A. Apoferritin, Ferritin (from horse 
spleen), Curcumin and all other chemicals were purchased 
from Sigma-Aldrich. H-Ferritin was kindly provided by 
Paola Turano (Center for Magnetic Resonance, University 
of Florence Italy) and prepared as described in [31, 32]. 
The loading of Curcumin and Gd-HPDO3A in the iron 
free Apoferritin cavity was carried out as described 
previously [22]. Briefly, the dissociation of Apoferritin 
into its subunits was done by lowering the pH of the 
4.1 × 10−6 M protein solution (8 mL) to pH 2 using 1 M 
HCl and maintaining this low pH for about 15 minutes. 
Afterwards, 50 μL of a Curcumin solution in DMSO (200 
mg/mL) and 2 mL 0.5 M Gd-HPDO3A were added to 
the Apoferritin solution. Then the pH was adjusted to 7.4 
using 1 M NaOH. The resulting solution was stirred at 
room temperature for 2 hours, centrifuged, purified by gel 
filtration (Superdex G25 Column, Amersham) and dialysis. 
The solution was then concentrated using Vivaspin 
centrifugal concentrators (50 000 MWCO, Sigma-
Aldrich). At the end of this process the concentrations of 
the protein and of Curcumin were measured by Bradford 
assay (using bovine serum albumin as a standard) and 
spectrophotometrically at 430 nm in ethanol, respectively. 
The final Gd concentration was determined by inductively 
Table 1: Percentage of mice whose tumor regressed (responders) or grew (non responders) in the three groups
APO-Curcumin Apoferritin Untreated
Responders 5/8 (62.5%) 1/10 (10%) 0/11 (0%)
Non Responders 3/8 (37.5%) 9/10 (90%) 11/11 (100%)
Data were cumulated from two independent and concordant experiments. APO-Curcumin vs Apoferritin treated mice: 
P = 0,043; Apoferritin treated mice vs Untreated mice: P = 0.47; APO-Curcumin treated mice vs Untreated mice: 
P = 0.0048, Chi square test.
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coupled plasma mass spectrometry (ICP-MS) (Element-2; 
Thermo-Finnigan). Sample digestion was performed with 
2 mL of concentrated HNO
3
 (70%) under microwave 
heating (Milestone MicroSYNTH Microwave Labstation).
Cell lines
MDA-MB-231 were purchased from LGC 
Standards and grown in DMEM (Invitrogen Corp.) 
supplemented with 10% FBS (Sigma-Aldrich). TUBO 
cells [44] were generated from a spontaneous tumor of 
Her2/neu transgenic (BALB-neuT) mice [45] and were 
cultured in DMEM supplemented with 20% FBS. All cells 
were tested negative for mycoplasma by PCR assay and 
passaged in our laboratory for fewer than six months after 
their resuscitation. For tumorsphere generation, cells were 
detached and plated in ultra-low attachment flasks (Sigma-
Aldrich) at 6 × 104 viable cells/mL in mammosphere 
medium, as previously reported [8].
Ferritin uptake experiments
MDA-MB-231, TUBO cells and their derived 
tumorspheres were incubated with increasing 
concentrations of Ferritin, Gd-APO-Curcumin and 
Apoferritin 24 hours post seeding. After 24 hours of 
incubation, cells were washed three times with ice-cold 
PBS and detached with trypsin/EDTA (Sigma-Aldrich). 
Then cells were lysed by sonication using an ultrasonic 
probe device (30% power). The Fe or Gd content in each 
cell line was determined by ICP-MS as described above. 
For MRI analysis (see below) cells were transferred into 
glass capillaries. The protein concentration was determined 
from cell lysates by the Bradford assay. The amounts 
of iron (measured by ICP-MS) internalized by cells 
were normalized to cell proteins concentration. 1 mg of 
proteins measured on cell lysate correspond to 3.1±0.3×106 
and 2.8±0.3×106 MDA-MB-231 differentiated cells 
and tumorspheres, respectively, and to 2.9±0.4×106 and 
3.8±0.35×106 TUBO differentiated cells and tumorspheres, 
respectively.
MRI
All the MR images were acquired on a Bruker 
Avance 300 spectrometer (7 T) equipped with a Micro 
2.5 microimaging probe (Bruker BioSpin). For in vitro 
determinations, glass capillaries containing 2 × 106 
cells were placed in an agar phantom and MRI was 
performed using a standard T1-weighted multislice spin-
echo sequence (TR/TE/NEX = 250/3.3/8, FOV = 1.2 
cm, NEX = number of excitations; FOV = field of view). 
T
2
-Weighted MRI images were obtained using a RARE 
sequence protocol (TR/TE/NEX = 5000/53/4; FOV= 
1.2cm; MTX 128x128). The T1/T2 relaxation times were 
calculated using a standard saturation recovery spin 
echo. The image of tumorspheres dispersed in agar were 
obtained using a 3D FLASH gradient echo (TR/TE/NEX 
= 3500/18/2; FOV=1.14 cm; MTX 128x128x128).
APO-FITC and APO-rhodamine preparation
2 mg/mL Apoferritin solution in 0.1 M sodium 
carbonate buffer at pH 9 was prepared. Fluorescein 
isothiocyanate (FITC, Sigma-Aldrich) or Rhodamine 
isothiocyanate (Rhod) were dissolved in anhydrous 
DMSO at 1 mg/mL. For each mg of protein, 50 μL of 
dye (FITC or Rhod) solution were added slowly (in 5 
μL aliquots) while stirring the protein solution. When 
all the required amount of dye solution had been added, 
the reaction mixture was incubated in the dark for 16 
hours at 4°C. Then NH
4
Cl was added to the solution to 
a final concentration of 50 mM, and it was incubated for 
other 2 hours at 4°C. The obtained Apoferritin solution 
was purified from non-entrapped dye with gel filtration 
using a G25 sephadex column, followed by dialysis. After 
purification, the solution was characterized in terms of 
protein concentration using the Bradford assay. The dye 
concentration was determined by measuring fluorescence 
(Horiba FluoroMax-4 spectrofluorometer), in Triton 0.1%, 
at 492/517 nm and 555/575 nm excitation/emission for 
FITC and Rhod, respectively.
APO-Rhodamine uptake experiments
MDA-MB-231, TUBO cells and their derived 
tumorspheres were incubated with increasing 
concentrations of APO-Rhod 24 hours post seeding. After 
24 hours of incubation, cells were washed three times with 
ice-cold PBS and detached with trypsin/EDTA. Then cells 
were lysed by sonication using an ultrasonic probe device 
(30% power) and rhodamine concentration in the cytosolic 
extracts was determined by measuring fluorescence as 
described in the previous paragraph. Competition study 
has been performed by comparing fluorescence intensity 
of TUBO and MDA-MB-231 tumorspheres incubated with 
APO-Rhod 25 nM (protein concentration) in the presence 
and in the absence of H-Ferritin 250 nM for 24 hours. 
Fluorescence intensity (expressed as arbitrary units) was 
normalized to the total protein cell content.
Fluorescent microscopy
For SCARA5 detection, 3 × 105 TUBO and MDA-
MB-231 cells were plated on glass coverslips and left to 
adhere overnight at 37°C in a 5% CO
2
 incubator. 1 × 105 
tumorsphere-derived cells were cytospinned (Cytospin 4, 
ThermoScientific) to glass slides. Then, cells were fixed 
with 4% formaldehyde solution in PBS (Sigma-Aldrich) 
and stained with an anti-SCARA5 antibody (Thermo 
Scientific), as previously described [25]. To visualize 
the internalization of Apoferritin, 6 × 105 disaggregated 
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TUBO-derived tumorspheres were incubated for 2 
hours at 37°C with APO-Rhod (0,47 μM in Rhod and 
0,073 μM in Apoferritin). Cells were then washed twice 
with ice-cold PBS, cytospinned to glass slides, fixed in 
cooled methanol for 10 min and permeabilized in cooled 
acetone for 1 min. Slides were then stained with anti-
EEA1 (Cell Signaling Technology) or with anti-LAMP-1 
(Santa Cruz Biotechnology) antibodies and visualized 
with AlexaFluor488 goat anti-rabbit or goat anti-mouse 
AlexaFluor488 secondary antibodies (Invitrogen), 
respectively. Cells were visualized with an ApoTome 
fluorescence microscope (Zeiss). Photographs were 
taken by using a digital CCD camera and images were 
processed using the AxioVision 4.8 software. The mean 
corrected total cell fluorescence (CTCF) was calculated 
on at least 100 cells per sample, using the following 
equation: CTCF = Integrated Density of selected cell - 
(Area of selected cell x Mean fluorescence of background 
readings). All measurements were performed using the 
ImageJ software.
Flow cytometric (FACS) analysis
Cells cultured as monolayers and their derived 
tumorspheres were incubated for different time intervals 
in the presence or absence of APO-Curcumin, free 
Curcumin, at a final Curcumin concentration of 50 μM, 
or Apoferritin (0.22 μM). Cells were then harvested 
and subsequently disaggregated using enzymatic and 
mechanical dissociation and washed in PBS supplemented 
with 0.2% BSA and 0.01% sodium azide (Sigma-
Aldrich). Cells were then stained with the Annexin V 
apoptosis detection kit (eBioscience) according to the 
manufacturer's instructions. The amount of cell death 
induced by the treatments was calculated as ratio among 
the percentage of Annexin V+ and propidium iodide (PI)+ 
cells in treated samples compared to control cells.
To quantify APO-FITC uptake, cells were cultured 
with APO-FITC (1μM in FITC and 0.3 μM in APO) for 24 
hours, then dissociated and stained with Alexa-Fluor647-
conjugated anti-Sca-1 monoclonal antibody (Biolegend) 
as previously described [8]. All samples were analyzed 
using a CyAn ADP Flow Cytometer and the Summit 4.3 
software (Beckman Coulter).
CSC self-renewal assay
Tumorspheres generated from MDA-MB-231 and 
TUBO cells were dissociated after 5 days of culture 
and plated at the density of 6 × 104 cells/mL in ultra 
low attachment six-well dishes in presence or not of 
APO-Curcumin, free Curcumin, at a final Curcumin 
concentration of 50 μM, or Apoferritin 0.22 μM. The total 
number of tumorspheres in each well was counted after 96 
hours of culture and reported as number of tumorspheres 
generated per 103 cells plated [8].
Cell transfection
200 pmol of siRNA specific for SCARA5 
(MSS291462) or negative control scrambled siRNA 
(Stealth RNAi Negative Control Hi-GC) were incubated 
with 10 μL Lipofectamin 2000 and diluted in Opti-
MEM Reduced Serum Media (all from Thermo Fisher 
Scientific) according to the manifacturer’s instructions. 
1 × 106 TUBO tumorsphere-derived cells suspended in 2 
mL tumorsphere growth medium were incubated with the 
transfection mix and harvested after 24, 48 or 72 hours and 
used for further experiments.
Western blotting
Cells were lysed with cell lysis buffer (0,5% NP-
40, 150 mM NaCl, 50 mM Tris-HCl, 0,25 mM EDTA, 1 
mM DTT, 1 mM Na
3
VO
4
 and 1:2000 protease inhibitor 
cocktail (all from Sigma-Aldrich)) as in [46]. 40 μg total 
proteins were resolved by SDS-PAGE and electroblotted 
onto PVDF membranes. After blocking with non-
fat dry milk diluted in Tris-Buffered Saline – Tween 
(TTBS) 0,05%, membranes were probed with rabbit 
anti-SCARA5 (Santa Cruz Biotechnology) or mouse 
anti-vinculin (Santa Cruz Biotechnology) antibodies 
followed by HRP-conjugated anti-rabbit IgG or anti-
mouse IgG (all from Sigma-Aldrich) and visualized 
with the ECL Western blotting substrate (Thermo Fisher 
Scientific), using a ChemiDoc Touch Imaging System 
(Biorad).
In vivo experiments
BALB/c mice (Charles River Laboratories) were 
maintained at the Molecular Biotechnology Center, 
University of Turin, and treated in accordance with 
University Ethical Committee and European guidelines 
under Directive 2010/63. Mice were subcutaneously 
(s.c.) challenged with 1 × 104 tumorsphere-derived cells 
(TUBO) and treated intravenously (i.v.) with APO-
Curcumin (10 mg/Kg of Curcumin dose, corresponding 
to a protein dose of 53 mg/Kg) or Apoferritin (at the same 
protein dose) every three days, starting when they have 
developed a 2 mm mean diameter tumor, or left untreated. 
Tumor growth was monitored twice a week with a caliper 
and reported as the mean of two perpendicular diameters. 
When tumors reached 10 mm mean diameter, mice were 
euthanized for ethical reasons.
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